{"title":"加巴喷丁类与日本中草药Goshajinkigan联合治疗CIPN患者化疗时间更长、剂量更高。","authors":"Kanako Miyano, Yasuhito Uezono, Takuhiro Yamaguchi, Wataru Hashimoto, Satoshi Komoriya","doi":"10.1007/s12325-025-03173-z","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>In Japan, both gabapentinoids and the Japanese traditional herbal medicine goshajinkigan (GJG) are used to manage chemotherapy-induced peripheral neuropathy (CIPN); however, evidence for their effectiveness is inconclusive. Patients with CIPN experience reduced quality of life and often undergo reductions in dose or discontinuation of chemotherapy. Therefore, this retrospective cohort study used a real-world database to examine the efficacy of gabapentinoids and GJG therapy for patients with CIPN by evaluating chemotherapy duration and dose.</p><h3>Methods</h3><p>Data from 145,384 patients diagnosed with CIPN while receiving platinum- or taxane-based chemotherapy between April 1, 2008 and March 31, 2022 were stratified by CIPN treatment: simultaneous gabapentinoid (mirogabalin or pregabalin) plus GJG (prescription dates overlap); non-simultaneous gabapentinoid plus GJG (prescription dates do not overlap); gabapentinoid alone; GJG alone; and neither gabapentinoids nor GJG. Duration and dose of chemotherapy were the primary outcomes.</p><h3>Results</h3><p>Treatment with either a gabapentinoid or GJG alone was associated with longer duration and higher doses of chemotherapy versus neither gabapentinoids nor GJG in patients treated with carboplatin, cisplatin, or paclitaxel. Combined gabapentinoid plus GJG treatment elicited further longer duration and higher doses of chemotherapy versus gabapentinoid alone or GJG alone in patients treated with carboplatin, oxaliplatin, cisplatin, paclitaxel, or docetaxel. When stratified by cancer type, similar trends were observed regarding combination gabapentinoid plus GJG treatment among patients with colorectal cancer treated with oxaliplatin and patients with gastric, lung, or breast cancer treated with paclitaxel.</p><h3>Conclusion</h3><p>Combination treatment with gabapentinoid plus GJG might prevent reductions in dose or discontinuation of chemotherapy, and might be effective for the treatment of CIPN.</p></div>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":"42 6","pages":"2833 - 2852"},"PeriodicalIF":3.4000,"publicationDate":"2025-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1007/s12325-025-03173-z.pdf","citationCount":"0","resultStr":"{\"title\":\"Co-treatment with Gabapentinoid and Japanese Herbal Medicine Goshajinkigan for CIPN is Associated with Longer Duration and Higher Dose of Chemotherapy\",\"authors\":\"Kanako Miyano, Yasuhito Uezono, Takuhiro Yamaguchi, Wataru Hashimoto, Satoshi Komoriya\",\"doi\":\"10.1007/s12325-025-03173-z\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Introduction</h3><p>In Japan, both gabapentinoids and the Japanese traditional herbal medicine goshajinkigan (GJG) are used to manage chemotherapy-induced peripheral neuropathy (CIPN); however, evidence for their effectiveness is inconclusive. Patients with CIPN experience reduced quality of life and often undergo reductions in dose or discontinuation of chemotherapy. Therefore, this retrospective cohort study used a real-world database to examine the efficacy of gabapentinoids and GJG therapy for patients with CIPN by evaluating chemotherapy duration and dose.</p><h3>Methods</h3><p>Data from 145,384 patients diagnosed with CIPN while receiving platinum- or taxane-based chemotherapy between April 1, 2008 and March 31, 2022 were stratified by CIPN treatment: simultaneous gabapentinoid (mirogabalin or pregabalin) plus GJG (prescription dates overlap); non-simultaneous gabapentinoid plus GJG (prescription dates do not overlap); gabapentinoid alone; GJG alone; and neither gabapentinoids nor GJG. Duration and dose of chemotherapy were the primary outcomes.</p><h3>Results</h3><p>Treatment with either a gabapentinoid or GJG alone was associated with longer duration and higher doses of chemotherapy versus neither gabapentinoids nor GJG in patients treated with carboplatin, cisplatin, or paclitaxel. Combined gabapentinoid plus GJG treatment elicited further longer duration and higher doses of chemotherapy versus gabapentinoid alone or GJG alone in patients treated with carboplatin, oxaliplatin, cisplatin, paclitaxel, or docetaxel. When stratified by cancer type, similar trends were observed regarding combination gabapentinoid plus GJG treatment among patients with colorectal cancer treated with oxaliplatin and patients with gastric, lung, or breast cancer treated with paclitaxel.</p><h3>Conclusion</h3><p>Combination treatment with gabapentinoid plus GJG might prevent reductions in dose or discontinuation of chemotherapy, and might be effective for the treatment of CIPN.</p></div>\",\"PeriodicalId\":7482,\"journal\":{\"name\":\"Advances in Therapy\",\"volume\":\"42 6\",\"pages\":\"2833 - 2852\"},\"PeriodicalIF\":3.4000,\"publicationDate\":\"2025-04-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://link.springer.com/content/pdf/10.1007/s12325-025-03173-z.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Advances in Therapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://link.springer.com/article/10.1007/s12325-025-03173-z\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Therapy","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s12325-025-03173-z","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
Co-treatment with Gabapentinoid and Japanese Herbal Medicine Goshajinkigan for CIPN is Associated with Longer Duration and Higher Dose of Chemotherapy
Introduction
In Japan, both gabapentinoids and the Japanese traditional herbal medicine goshajinkigan (GJG) are used to manage chemotherapy-induced peripheral neuropathy (CIPN); however, evidence for their effectiveness is inconclusive. Patients with CIPN experience reduced quality of life and often undergo reductions in dose or discontinuation of chemotherapy. Therefore, this retrospective cohort study used a real-world database to examine the efficacy of gabapentinoids and GJG therapy for patients with CIPN by evaluating chemotherapy duration and dose.
Methods
Data from 145,384 patients diagnosed with CIPN while receiving platinum- or taxane-based chemotherapy between April 1, 2008 and March 31, 2022 were stratified by CIPN treatment: simultaneous gabapentinoid (mirogabalin or pregabalin) plus GJG (prescription dates overlap); non-simultaneous gabapentinoid plus GJG (prescription dates do not overlap); gabapentinoid alone; GJG alone; and neither gabapentinoids nor GJG. Duration and dose of chemotherapy were the primary outcomes.
Results
Treatment with either a gabapentinoid or GJG alone was associated with longer duration and higher doses of chemotherapy versus neither gabapentinoids nor GJG in patients treated with carboplatin, cisplatin, or paclitaxel. Combined gabapentinoid plus GJG treatment elicited further longer duration and higher doses of chemotherapy versus gabapentinoid alone or GJG alone in patients treated with carboplatin, oxaliplatin, cisplatin, paclitaxel, or docetaxel. When stratified by cancer type, similar trends were observed regarding combination gabapentinoid plus GJG treatment among patients with colorectal cancer treated with oxaliplatin and patients with gastric, lung, or breast cancer treated with paclitaxel.
Conclusion
Combination treatment with gabapentinoid plus GJG might prevent reductions in dose or discontinuation of chemotherapy, and might be effective for the treatment of CIPN.
期刊介绍：
Advances in Therapy is an international, peer reviewed, rapid-publication (peer review in 2 weeks, published 3–4 weeks from acceptance) journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of therapeutics and interventions (including devices) across all therapeutic areas. Studies relating to diagnostics and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged.
The journal is of interest to a broad audience of healthcare professionals and publishes original research, reviews, communications and letters. The journal is read by a global audience and receives submissions from all over the world. Advances in Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of all scientifically and ethically sound research.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
